Peritoneal Malignancy Institute Basingstoke

Located at Basingstoke and North Hampshire Hospital

Part of Hampshire Hospital NHS Foundation Trust PELICAN IMPROVING MANAGEMENT FOR PATIENTS IMPACT WITH ADVANCED COLORECTAL TUMOURS

Colorectal Peritoneal Metastases

Faheez Mohamed Consultant Surgeon Peritoneal Malignancy Institute

Basingstoke



PMI Basingstoke Basingstoke and North Hampshire Hospital Aldermaston Road, Basingstoke, Hampshire RG24 9NA www.pmibasingstoke.com



Working in partnership with: Basingstoke Colorectal





Best outcomes

- Complete cytoreduction
- Limited disease
- Synchronous presentation
- Favourable biology (differentiation, time to recurrence)
- Response to adjuvant or neo adjuvant chemotherapy








Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer

Peritoneal Malignancy Institute Basingstoke

By Vic J. Verwaal, Serge van Ruth, Eelco de Bree, Gooike W. van Slooten, Harm van Tinteren, Henk Boot, and Frans A.N. Zoetmulder







JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Peritoneal Malignancy Institute Basingstoke



Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study

Dominique Elias, François Gilly, Florent Boutitie, F

523 patients 23 centres 1990-2007




Fig 1. Overall and disease-free survival rates of the 523 patients with peritoneal carcinomatosis of colorectal origin.






JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Peritoneal Malignancy Institute Basingstoke

Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study

Dominique Elias, François Gilly, Florent Boutitie, François Quenet, Jean-Marc Bereder, Baudouin Mansvelt,








Peritoneal Malignancy Institute Basingstoke

Keywords: peritoneal carcinomatosis; cytoreductive surgery; intraperitoneal chemotherapy

Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone

R Mirnezami¹, A M Mehta², K Chandrakumaran³, T Cecil³, B J Moran³, N Carr³, V J Verwaal^{2,5}, F Mohamed^{3,5} and A H Mirnezami*,4,5

¹Section of Biosurgery and Surgical Technology, Department of Surgery and Cancer, Imperial College London, St Mary's Hospital, 10th Floor QEQM Building, London W2 1NY, UK; ²Peritoneal Surface Malignancy Unit, Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands; ³Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, Hampshire RG24 9NA, UK and ⁴University of Southampton Cancer Sciences Division, Southampton University Hospital NHS Trust, Somers Cancer Research Building, Tremona road, Southampton SO166YD, UK



6





National Institute for Health and Clinical Excellence


Peritoneal Malignancy Institute Basingstoke






2.3 Efficacy

2.3.1 A systematic review of 4500 patients with peritoneal carcinomatosis of colorectal origin reported an overall median 5-year survival of 19% (16 studies).










ProphyloCHIP : Study Design

To improve PFS at 3 years from 40 to 65 months


Statistical Framework

- N = 160 (overall)
- Primary end point : PFS at 3 years
- Secondary end points :
 - -OS at 5 years
 - Peritoneal recurrence free survival at 5 years
 - Morbidity of 2nd look laparotomy and Toxicity of HIPEC



COLOPEC: Dutch Multicentre Study





Laparoscopy at 18 months: powered to detect 15% difference between arms







PRODIGE 7

